Buparlisib (BKM120), another pan-PI3K inhibitor, showed limited antitumor activity in patients with platinum-refractory R/M HNSCC, with a disease control rate of 49% and an ORR of only 3% (NCT01527877). This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.